HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Nathan P Wiederhold Selected Research

Invasive Pulmonary Aspergillosis

5/2015Efficacy of the investigational echinocandin ASP9726 in a guinea pig model of invasive pulmonary aspergillosis.
8/2013Prolyl endopeptidase activity in bronchoalveolar lavage fluid: a novel diagnostic biomarker in a guinea pig model of invasive pulmonary aspergillosis.
2/2013Interlaboratory and interstudy reproducibility of a novel lateral-flow device and influence of antifungal therapy on detection of invasive pulmonary aspergillosis.
8/2012Dry powder insufflation of crystalline and amorphous voriconazole formulations produced by thin film freezing to mice.
4/2012Prophylactic efficacy of single dose pulmonary administration of amphotericin B inhalation powder in a guinea pig model of invasive pulmonary aspergillosis.
3/2012Detection and measurement of fungal burden in a guinea pig model of invasive pulmonary aspergillosis by novel quantitative nested real-time PCR compared with galactomannan and (1,3)-β-D-glucan detection.
12/2009Comparison of lateral flow technology and galactomannan and (1->3)-beta-D-glucan assays for detection of invasive pulmonary aspergillosis.
6/2009Inhaled voriconazole for prevention of invasive pulmonary aspergillosis.
3/2008Assessment of serum (1->3)-beta-D-glucan concentration as a measure of disease burden in a murine model of invasive pulmonary aspergillosis.
7/2007Aerosolized nanostructured itraconazole as prophylaxis against invasive pulmonary aspergillosis.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Nathan P Wiederhold Research Topics

Disease

35Infections
06/2021 - 01/2005
17Invasive Fungal Infections
02/2021 - 12/2007
16Aspergillosis
01/2022 - 12/2003
13Body Weight (Weight, Body)
01/2020 - 02/2006
13Invasive Pulmonary Aspergillosis
05/2015 - 10/2004
12Invasive Candidiasis
08/2022 - 01/2008
11Mycoses (Diseases, Fungus)
12/2021 - 08/2003
8Mucormycosis
04/2021 - 07/2013
4Fusariosis
07/2021 - 01/2006
3Candidiasis (Moniliasis)
08/2022 - 01/2012
3Cryptococcal Meningitis
11/2018 - 01/2016
3Coccidioidomycosis
01/2018 - 12/2015
3Cryptococcosis
12/2016 - 02/2013
2Fever (Fevers)
06/2021 - 04/2017
2Cystic Fibrosis (Mucoviscidosis)
06/2021 - 03/2017
2Candidemia
07/2019 - 09/2013
2Chronic Granulomatous Disease
06/2019 - 01/2017
2Drug-Related Side Effects and Adverse Reactions
03/2018 - 01/2018
2Meningoencephalitis
02/2013 - 06/2012
2Pulmonary Edema
03/2010 - 09/2009
2Neoplasms (Cancer)
12/2005 - 01/2005
1Breakthrough Infections
06/2021
1Coinfection
06/2021
1Surgical Wound
06/2021
1Legg-Calve-Perthes Disease (Perthes Disease)
06/2021
1Wounds and Injuries (Trauma)
06/2021
1Pain (Aches)
06/2021
1Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
01/2021
1Leukemia
01/2021
1Myelodysplastic Syndromes (Myelodysplastic Syndrome)
01/2021
1scedosporiosis
01/2020
1Bacterial Infections (Bacterial Infection)
12/2019
1Granuloma
06/2019
1Weight Loss (Weight Reduction)
03/2019
1Diarrhea
03/2019
1Colitis
03/2019
1Ileitis
03/2019
1Pythiosis
03/2019
1Alopecia (Baldness)
01/2019

Drug/Important Bio-Agent (IBA)

18EchinocandinsIBA
10/2019 - 12/2007
14AzolesIBA
01/2022 - 06/2007
11posaconazoleFDA Link
06/2021 - 03/2010
11Fluconazole (Zonal)FDA LinkGeneric
01/2021 - 02/2013
10Caspofungin (Cancidas)FDA Link
11/2019 - 08/2003
9Voriconazole (Vfend)FDA LinkGeneric
01/2019 - 06/2009
7Antifungal AgentsIBA
01/2018 - 03/2008
7Pharmaceutical PreparationsIBA
01/2017 - 04/2005
7Amphotericin B (Amphotericin)FDA LinkGeneric
10/2015 - 02/2006
6isavuconazoleIBA
06/2021 - 01/2016
5Itraconazole (Sporanox)FDA LinkGeneric
01/2019 - 04/2006
5Micafungin (FK463)FDA Link
01/2017 - 08/2003
4olorofimIBA
07/2021 - 11/2016
4VT-1161IBA
01/2019 - 12/2015
3ibrexafungerpIBA
08/2022 - 01/2018
3Investigational DrugsIBA
08/2022 - 12/2015
3liposomal amphotericin BFDA Link
04/2021 - 07/2013
3EnzymesIBA
01/2020 - 01/2017
3VT-1598IBA
01/2019 - 01/2018
3galactomannanIBA
04/2016 - 12/2009
3polyglucosanIBA
04/2016 - 03/2008
2CytokinesIBA
04/2021 - 06/2007
2Pentamidine (NebuPent)FDA LinkGeneric
02/2021 - 01/2006
2T-2307IBA
02/2021 - 02/2015
2ProdrugsIBA
01/2020 - 01/2020
21-aminobenzotriazoleIBA
01/2020 - 01/2020
2TriazolesIBA
01/2020 - 01/2019
2APX001AIBA
01/2020 - 01/2015
2RezafunginIBA
10/2019 - 11/2018
2Anti-Bacterial Agents (Antibiotics)IBA
03/2019 - 06/2015
2Ergosterol (Lumisterol)IBA
01/2019 - 03/2018
2VT-1129IBA
11/2018 - 01/2018
2glucan synthaseIBA
01/2018 - 08/2003
2Indicators and Reagents (Reagents)IBA
04/2016 - 01/2005
2Biomarkers (Surrogate Marker)IBA
08/2013 - 03/2008
2AnidulafunginFDA Link
05/2007 - 08/2003
2Adrenal Cortex Hormones (Corticosteroids)IBA
02/2006 - 12/2003
2GliotoxinIBA
12/2005 - 01/2005
1ChemokinesIBA
04/2021
1venetoclaxIBA
01/2021
1DNA ProbesIBA
11/2020
1Glycosylphosphatidylinositols (Glycosyl-Phosphatidylinositol)IBA
01/2020
1mannoproteinsIBA
01/2020
1Volatile Oils (Essential Oils)IBA
12/2019
1NADPH Oxidases (NAD(P)H oxidase)IBA
06/2019
1Formaldehyde (Formol)FDA Link
03/2019
1Coloring Agents (Dyes)IBA
03/2019
1ImmunosorbentsIBA
03/2019
1Methenamine (Hexamine)IBA
03/2019
1ParaffinIBA
03/2019
1ebericolIBA
01/2019
1HMGB1 Protein (HMG1)IBA
01/2019
1SterolsIBA
01/2019
1ebselenIBA
10/2018

Therapy/Procedure

29Therapeutics
01/2022 - 12/2003
3Salvage Therapy
01/2019 - 03/2010
2Lung Transplantation
06/2021 - 03/2017
1Hip Replacement Arthroplasty (Total Hip Replacement)
06/2021
1Remission Induction
01/2021
1Drug Therapy (Chemotherapy)
01/2021
1Intraperitoneal Injections
11/2019